Eagle Pharmaceuticals Inc buy klostergang
Start price
23.06.15
/
50%
€77.64
Target price
23.12.15
€95.00
Performance (%)
9.73%
End price
23.12.15
€85.20
Summary
This prediction ended on 23.12.15 with a price of €85.20. With a performance of 9.73%, the BUY prediction by klostergang for Eagle Pharmaceuticals Inc closed with a slight gain. klostergang has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Eagle Pharmaceuticals Inc | -2.703% | -2.703% | -67.470% | -86.634% |
iShares Core DAX® | -0.612% | 0.567% | 12.585% | 14.838% |
iShares Nasdaq 100 | -3.018% | -3.205% | 26.208% | 38.328% |
iShares Nikkei 225® | -2.647% | 0.330% | 9.482% | 5.652% |
iShares S&P 500 | -1.932% | -1.126% | 23.191% | 38.791% |
Comments by klostergang for this prediction
In the thread Eagle Pharmaceuticals Inc diskutieren
Fly like :
- Eagle Pharmaceuticals (NASDAQ:EGRX) submits a New Drug Application (NDA) to the FDA for a stable liquid intravenous formulation (ready-to-use or RTU) of bivalirudin for the treatment of patients undergoing percutaneous coronary intervention (PCI) in the following scenarios: with the use of a glycoprotein IIb/IIIa inhibitor or at risk of heparin-induced thrombocytopenia and thrombosis syndrome and patients with unstable angina undergoing percutaneous transluminal coronary angioplasty.
- RTU bivalirudin, intended for use with aspirin, contains the same active ingredient as The Medicines Company's (NASDAQ:MDCO) Angiomax (bivalirudin), but eliminates the need for reconstitution/dilution.
- Angiomax generated ~$600M in sales in 2014.
- Bivalirudin is an anticoagulant that inhibits thrombin.
(Laufzeit überschritten)